Arachidonyl glycine， the conjugate of arachidonic acid and glycine produced in mammalian brain， skin， and spinal cord， is a structural analog of anandamide （AEA） that is reported to have analgesic activities in whole animal experiments. It has poor affinity for the central cannabinoid （CB1） receptor， high-affinity for the G protein-coupled receptor GPR-18， and is metabolically regulated by fatty acid amide hydrolase （FAAH） activity. LinGly is an endogenous homolog of linoleoyl ethanolamide， an arachidonyl glycine. It inhibits the hydrolysis of AEA in FAAH-containing N18TG2 cell membranes with an IC50 value of ~25 uM， which is less potent than that of arachidonyl glycine （IC50 = 7 uM）. The biological significance of LinGly has not yet been determined.
產品描述
An endogenous homolog of arachidonyl glycine that inhibits AEA hydrolysis in FAAH-containing N18TG2 cell membranes with an IC50 value of 25 uM
